Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 October 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predictor of clinical relapse among patients with ulcerative colitis

This month's issue of the American Journal of Gastroenterology explores histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis.

News image

fiogf49gjkf04
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."
,
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."
,
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."

Am J Gastroenterol 2016; 111:1692–1701
13 December 2016

Go to top of page Email this page Email this page to a colleague

 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 23 October 2017 
Irradiated rectal cancer and chemoradiotherapy
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 20 October 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Surgical anastomosis at 1-year colorectal cancer surveillance
 19 October 2017 
Current management of chylous ascites
 18 October 2017 
Hep E seroprevalence and hemodialysis
 18 October 2017 
Prebiotic and changes in the human gut microbiota
 18 October 2017 
Predicting recurrence after curative rectal cancer surgery
 17 October 2017 
Laparoscopic surgery use in Medicare patients with colon cancer
 17 October 2017 
Medication nonadherence and health care costs
 17 October 2017 
Asthma and IBD development
 16 October 2017 
Colorectal cancer screening and postpolypectomy surveillance colonoscopy
 16 October 2017 
Continuity of care after colorectal surgery
 16 October 2017 
Breastfeeding and the risk of IBD
 13 October 2017 
Treating patients with HCV and severe renal impairment
 13 October 2017 
Blood pressure management during abdominal surgery
 13 October 2017 
Food elimination diets for eosinophilic esophagitis
 12 October 2017 
Global recurrence of H. pylori
 12 October 2017 
Colonoscopy in an organized colorectal cancer screening program 
 12 October 2017 
Predicting advanced fibrosis in chronic hepatitis B
 11 October 2017 
Fecal microbiota transplantation for ulcerative colitis
 11 October 2017 
Sexual functioning in Hep C
 11 October 2017 
Ulcerative proctitis in pediatric-onset UC
 10 October 2017 
Quality standards in upper gastrointestinal endoscopy
 10 October 2017 
Eosinophilic esophagitis and swallowed topical corticosteroids
 10 October 2017 
Follow-up of positive results on fecal blood tests
 09 October 2017 
Diverticulitis and emergency department burden
 09 October 2017 
Global recurrence rate of H. pylori
 09 October 2017 
Clostridium difficile infection after ileostomy reversal
 06 October 2017 
Predicting nontreatment for Hep C
 06 October 2017 
Cow's milk–based formula and development of celiac disease
 06 October 2017 
Propofol for outpatient colonoscopy
 05 October 2017 
Pediatric candidates on the transplant wait list
 05 October 2017 
Incidence of sepsis in the USA
 05 October 2017 
Quality of life after chemoradiation in rectal cancer
 04 October 2017 
Peptic ulcer disease diagnosed in acute upper endoscopy
 04 October 2017 
Clinical practice guidelines in colon cancer
 04 October 2017 
Rural residence and risk of IBD
 03 October 2017 
Novel candidate risk genes for IBD
 03 October 2017 
Antibody tests and detecting celiac disease
 03 October 2017 
Environmental factors and IBD
 02 October 2017 
Full publication of Gastroenerology abstracts
 02 October 2017 
Interferon-free therapy in advanced liver disease
 02 October 2017 
Burden of NAFLD with advanced fibrosis in the USA
 29 September 2017 
Inpatient Gastroenterology training experience
 29 September 2017 
Proteomic analysis of IBD
 28 September 2017 
Social networking-based discussion group by ERCP doctors
 28 September 2017 
Incidence of biopsy-verified celiac disease
 27 September 2017 
Predictors of nonadherence in IBD
 27 September 2017 
Hep C treatment in the era of direct-acting anti-viral agents
 27 September 2017 
Function of trypsin-3 in IBS
 26 September 2017 
Chronic pancreatitis and pancreatic cancer risk
 26 September 2017 
Factors associated with the risk of metachronous gastric neoplasm
 26 September 2017 
Treatment of hyperactive delirium in advanced cancer
 25 September 2017 
Lenalidomide for advanced liver cancer
 25 September 2017 
Silibinin nanoparticles inhibit HCV infection

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us